-
3 weeks ago | 
alsnewstoday.com | Juliet Taylor
Sometime in my mid-40s, I wrote a list of goals I wanted to achieve before turning 50. I no longer have the list, but I remember a few things on it: Learn a second language. Complete one half-marathon each year. And my then-favorite, visit 50 countries by the time I turned 50. At the time, those goals seemed attainable and were aligned with the kind of person I wanted to be — healthy, curious, and motivated. That was before my late husband, Jeff, was diagnosed with ALS when I was 48 and he was 58.
-
1 month ago | 
alsnewstoday.com | Juliet Taylor |Kristin Neva |Patricia Inacio
The weeks immediately following my late husband’s ALS diagnosis were the scariest and most unsettling of my life. Even with Jeff’s physical symptoms pointing toward ALS, nothing could’ve prepared us to actually hear those words when they were delivered in a windowless examination room in Baltimore, in November 2018. In many respects, those initial days of shock and despair were more difficult than any that followed.
-
1 month ago | 
alsnewstoday.com | Lindsey Shapiro |Juliet Taylor |Marisa Wexler |Joana Carvalho
Certain subsets of natural killer (NK) cells, a part of the immune system, were elevated in the blood of people with amyotrophic lateral sclerosis (ALS), where they showed altered gene activity and signaling patterns, a study found. One subset was associated with altered immune signaling, while another was linked to neurodegeneration.
-
1 month ago | 
alsnewstoday.com | Margarida Maia |Lindsey Shapiro |Dagmar Munn |Juliet Taylor
Health Canada has invited Neurosense Therapeutics to discuss the potential for giving conditional approval to PrimeC in treating amyotrophic lateral sclerosis (ALS), according to a company filing with the U.S. Securities and Exchange Commission.
-
1 month ago | 
alsnewstoday.com | Kristin Neva |Juliet Taylor |Dagmar Munn
After decades of classic cross-country skiing, I realized that the groomed track is too wide for me, and it got me thinking how difficult it is to find single solutions to help everybody with ALS. We had springlike weather this past week in Michigan’s Upper Peninsula, and I got out on Michigan Tech’s ski trails on a 50-degree afternoon. Getting exercise and being in nature help me manage the stress of my husband’s ongoing decline because of ALS.
-
2 months ago | 
alsnewstoday.com | Margarida Maia |Lindsey Shapiro |Juliet Taylor |Kristin Neva
Using a smartphone app to self-assess ALS Functional Rating Scale-Revised (ALSFRS-R) scores, a standardized measure of amyotrophic lateral sclerosis (ALS) severity, may be as reliable as clinic-based assessments, a study reports. Its findings suggest this app could be a useful digital tool for remote monitoring of ALS, allowing patients to track how fast their disease is progressing at home while awaiting a next clinic visit.
-
2 months ago | 
alsnewstoday.com | Juliet Taylor |Kristin Neva
When I was growing up, many of my neighbors participated in the U.S. Naval Academy Sponsor Program, as we lived just a few miles from the school’s campus in Annapolis, Maryland. Under the program, local families “adopted” midshipmen, offering a home away from home to the students, who could come over to watch television, do laundry, and enjoy some time away from the pressures of the respected but rigorous service academy.
-
2 months ago | 
alsnewstoday.com | Dagmar Munn |Marisa Wexler |Juliet Taylor |Margarida Maia
I’ve been living with ALS for the past 15 years, and although it’s filled my days with life lessons and moments of gratitude, there have also been many twists of irony. One of the biggest ironies? I sometimes feel out of place in a community that’s so warm and welcoming. Why? Because I’m what’s called a “slow progressor.”While ALS is known for symptoms that quickly and constantly worsen, mine have advanced at a much slower pace compared with most patients.
-
Feb 14, 2025 | 
alsnewstoday.com | Juliet Taylor |Lindsey Shapiro |Kristin Neva
A photo I came across this week from when my late husband, Jeff, was living with ALS flooded me with emotions. It was taken in November 2019, the month we moved into an accessible home. His ALS was advancing rapidly at the time, which prompted our move. He could no longer walk, but I could still transfer him unaided to a scooter, power wheelchair, or reclining armchair.
-
Jan 31, 2025 | 
alsnewstoday.com | Lindsey Shapiro |Steve Bryson |Juliet Taylor
AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who haven’t completely lost physical function, according to a company update. The trial, called AB23005, will replace the AB19001 Phase 3 clinical trial (NCT03127267) that was hindered by slow recruitment.
